EXACT Sciences Corporation (EXAS) was Reiterated by Jefferies to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 20 from a previous price target of $13 . Jefferies advised their investors in a research report released on Jul 27, 2016.
Many Wall Street Analysts have commented on EXACT Sciences Corporation. Company shares were Reiterated by Craig Hallum on Jul 27, 2016 to “Buy”, Firm has raised the Price Target to $ 26 from a previous price target of $18 .Craig Hallum Upgraded EXACT Sciences Corporation on Jun 16, 2016 to ” Buy”, Price Target of the shares are set at $18.Shares were Downgraded by Mizuho on May 4, 2016 to ” Neutral” and Lowered the Price Target to $ 6.50 from a previous price target of $12 .
On the company’s financial health, EXACT Sciences Corporation reported $-0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.09 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $-0.55. The company had revenue of $21.20 million for the quarter, compared to analysts expectations of $18.50 million. The company’s revenue was up 161.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.44 EPS.
EXACT Sciences Corporation opened for trading at $16 and hit $17.5 on the upside on Thursday, eventually ending the session at $17.32, with a gain of 2.97% or 0.5 points. The heightened volatility saw the trading volume jump to 1,92,12,242 shares. Company has a market cap of $1,703 M.
In a different news, on Jul 27, 2016, Graham Peter Lidgard (Chief Science Officer) sold 7,383 shares at $14.82 per share price. According to the SEC, on Jul 27, 2016, Maneesh Arora (COO) sold 7,359 shares at $14.82 per share price. On Jul 5, 2016, D Scott Coward (SVP and General Counsel) sold 1,644 shares at $12.28 per share price, according to the Form-4 filing with the securities and exchange commission.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers its test includes a protein marker to detect blood in the stool utilizing an antibody?based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre?cancerous lesions or polyps and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test affected patients can be referred to colonoscopy during which the polyps or lesions can be removed. The company’s test also detects blood in stool utilizing an antibody based FIT test.